Literature DB >> 15582530

Use of long synthetic peptides to study the antigenicity and immunogenicity of the Plasmodium vivax circumsporozoite protein.

Sócrates Herrera1, Anilza Bonelo, Blanca Liliana Perlaza, Anais Zully Valencia, Catherine Cifuentes, Silvia Hurtado, Gustavo Quintero, José Alejandro López, Giampietro Corradin, Myriam Arévalo-Herrera.   

Abstract

Three long synthetic peptides corresponding to amino (N), repeat (R) and carboxyl (C) regions of the Plasmodium vivax circumsporozoite (CS) protein were synthesised and used to assess their potential as vaccine candidates. Antigenicity studies were carried out using human blood samples from residents of a malaria-endemic area of Colombia, and immunogenicity was tested in Aotus monkeys. The N and C peptides spanned the total native amino and carboxyl flanking regions, whereas the R peptide corresponded to a construct based on the first central nona-peptide repeated in tandem three times and colinearly linked to a universal T-cell epitope (ptt-30) derived from tetanus toxin. All three peptides had been shown previously to contain several B-, T-helper (Th) and Cytotoxic T Lymphocytes (CTL) epitopes. Sixty-one percent of the human sera reacted with the R region, whereas 35 and 39% of the samples had antibodies against the N and C peptides, respectively. Human Peripheral Blood Mononuclear Cells (PBMC) showed higher levels of IFN-gamma than IL-4 when stimulated with peptides containing Th epitopes. Aotus monkeys immunised with the peptides formulated in either Montanide ISA720 or Freund's adjuvants produced strong antibody responses that recognised the peptide immunogens and the native circumsporozoite protein on sporozoites. Additionally, high IFN-gamma production was induced when Aotus lymphocytes were stimulated in vitro with each of the three peptides. We observed boosting of antibody responses and IFN-gamma production by exposure to live sporozoites. These results confirm the high antigenicity and immunogenicity of such synthetic polypeptides and underline their vaccine potential.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582530     DOI: 10.1016/j.ijpara.2004.10.009

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  23 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

3.  Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51.

Authors:  Sócrates Herrera; Olga Lucía Fernández; Omaira Vera; William Cárdenas; Oscar Ramírez; Ricardo Palacios; Mario Chen-Mok; Giampietro Corradin; Myriam Arévalo-Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.

Authors:  Myriam Arévalo-Herrera; Omaira Vera; Angélica Castellanos; Nora Céspedes; Liliana Soto; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  Immune responses and protection of Aotus monkeys immunized with irradiated Plasmodium vivax sporozoites.

Authors:  Alejandro Jordán-Villegas; Anilza Bonelo Perdomo; Judith E Epstein; Jesús López; Alejandro Castellanos; María R Manzano; Miguel A Hernández; Liliana Soto; Fabián Méndez; Thomas L Richie; Stephen L Hoffman; Myriam Arévalo-Herrera; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

6.  High-throughput molecular diagnosis of circumsporozoite variants VK210 and VK247 detects complex Plasmodium vivax infections in malaria endemic populations in Papua New Guinea.

Authors:  Cara N Henry-Halldin; Daphne Sepe; Melinda Susapu; David T McNamara; Moses Bockarie; Christopher L King; Peter A Zimmerman
Journal:  Infect Genet Evol       Date:  2010-12-13       Impact factor: 3.342

7.  Plasmodium vivax parasites alter the balance of myeloid and plasmacytoid dendritic cells and the induction of regulatory T cells.

Authors:  Kulachart Jangpatarapongsa; Patchanee Chootong; Jetsumon Sattabongkot; Kesinee Chotivanich; Jeeraphat Sirichaisinthop; Sumalee Tungpradabkul; Hajime Hisaeda; Marita Troye-Blomberg; Liwang Cui; Rachanee Udomsangpetch
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

8.  Plasmodium vivax circumsporozoite genotypes: a limited variation or new subspecies with major biological consequences?

Authors:  Wanessa C Souza-Neiras; Luciane M Storti-Melo; Gustavo C Cassiano; Vanja S C A Couto; Alvaro A R A Couto; Irene S Soares; Luzia H Carvalho; Maristela G Cunha; Marinete M Póvoa; Socrates Herrera; Myriam A Herrera; Andrea R M Rossit; Claudia M A Carareto; Ricardo L D Machado
Journal:  Malar J       Date:  2010-06-23       Impact factor: 2.979

Review 9.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

Review 10.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.